Discussion on the efficacy and control period of trifluridine and tipiracil (Lancever)

Trifluridine and tipiracil (Lonsurf) is an innovative oral anti-cancer drug combination, which is an exquisite fusion of the nucleoside analogue trifluridine with anti-cancer activity and the enhancer tipiracil. The dual mechanism of this drug is that tipiracil not only enhances the efficacy of trifluridine, but also independently demonstrates its unique ability to combat angiogenesis. Regardingthe question of "how long can drugs control the disease?" is a complex issue that may be affected by multiple factors.

The efficacy of trifluridine and tipiracil has been solidly demonstrated in cutting-edge research conducted in Japan. A pivotal Phase II study and subsequent Phase III clinical trials confirmed the safety and efficacy of this drug combination in treating patients with advanced cancer. Especially in the large trial called RECOURSE, patients who received trifluridine and tipiracil showed longer overall survival compared with conventional placebo, from an average of 5.3 months to 7.1 months. But the drug's effects are not limited to survival prolongation. In this trial, although the overall response rate was low at 1.6%, up to 44% of patients achieved significant progress in disease stabilization and control, far exceeding the 16% in the placebo group.

Different patients will have completely different responses to this drug combination due to multiple factors such as genetic differences, disease progression and lifestyle. Although research shows that its effective control period can usually last from several months to about a year, doctors still need to carefully weigh the pros and cons when prescribing, understand the patient's specific situation, and follow the doctor's guidance for treatment.